KRAS and non-small cell lung carcinoma: A phase II study comparing the MEK inhibitor trametinib with docetaxel involving pre-treated, advanced, KRAS+ NSCLC was also negative (mPFS 12 vs. 11 weeks; p = 0.5197) [78].